Portfolio Companies News
March 29, 2023Vicore receives Innovation Passport...
Stockholm, March 29, 2023 – Vicore Pharma Holding AB (publ) (“Vicore”), unlocking the potential of a new class of drugs – angiotensin II type 2-receptor agonists (ATRAGs), today announces that the UK MHRA (Medicines and Healthcare products Regulatory Agency) has awarded Vicore Innovation Pa... read more
March 28, 2023Oncopeptides receives a research gr...
March 28, 2023 Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development and commercialization of therapies for difficult-to-treat hematological diseases, today announced that the company has received a research grant of 3 MSEK from Sweden´s Innovation... read more
March 20, 2023Fusion Pharmaceuticals Announces Fi...
HAMILTON, ON and BOSTON, March 20, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the first patient has been dosed in ... read more
March 16, 2023Spruce Biosciences Reports Full Yea...
CAHmelia-203 in Adult Classic CAH Surpasses 50% Enrollment Private Placement Financing of $53.6 million in Gross Proceeds with Top-Tier Healthcare Investors Strategic Partnership and Exclusive Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Tilda... read more
March 16, 2023Fusion Pharmaceuticals Announces Fo...
Company recently acquired IND for ongoing Phase 2 clinical trial evaluating 225Ac-PSMA I&T, a small molecule radiopharmaceutical targeting PSMA positive mCRPC FPI-1434 preliminary Phase 1 data expected in Q2 2023 FPI-1966 and FPI-2059 Phase 1 trials open and recruiting patients St... read more
February 21, 2023Q4 2022 General Market Overview
March 06, 2023Artikel i Life Science Sweden
November 29, 2021HealthCap’s 25th company anniversary!
Since the start in 1996, HealthCap funds have invested in 126 portfolio companies.
47 of the portfolio companies have been taken public on fourteen different markets.
31 of the portfolio companies pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 12 companies with a valuation of USD 1 billion or more.
HealthCap is a European venture capital firm investing exclusively and globally in life sciences. The investment strategy focuses on diseases with high unmet medical needs and breakthrough therapies that have the potential to be transformative...Read more